FG-3246 targets CD46 in mCRPC patients, focusing on those who progressed on ARSI without prior taxane therapy. The trial will evaluate FG-3246's safety, efficacy, and pharmacokinetics, alongside ...

Fosnight described how stigma itself becomes a barrier to care, even though effective diagnostic and treatment options are available. In an interview, Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, ...

"Liquid biopsy analysis provides a noninvasive and facile tool for early detection, diagnosis, and recurrence surveillance of urological cancer," writes Jim Lu, MD, PhD.

Adding the investigational agent masitinib to standard frontline docetaxel significantly reduced the risk of disease progression or death in men with metastatic castration-resistant prostate cancer ...